Newsbenzinga
Cullinan Therapeutics Announces First Patient Dosed In Pivotal Phase 2 Study Of CLN-049 In Relapsed AML; Expects Phase 1 Update In December
· Published
Article summary
Please check the source for details.
An excerpt from the original article.
Comments —
Loading comments…